Vakcína Sinopharm WIBP proti covidu-19 (Czech Wikipedia)

Analysis of information sources in references of the Wikipedia article "Vakcína Sinopharm WIBP proti covidu-19" in Czech language version.

refsWebsite
Global rank Czech rank
5th place
3rd place
2nd place
4th place
5,225th place
2,661st place
4th place
8th place
low place
low place
1st place
1st place
1,127th place
low place
low place
low place
49th place
92nd place
7th place
43rd place
1,231st place
6,550th place

cayetano.edu.pe

channelnewsasia.com

  • Sinopharm's Wuhan affiliate boosts COVID-19 shot annual capacity to 1 billion doses. CNA [online]. [cit. 2021-11-05]. Dostupné v archivu pořízeném z originálu dne 2021-11-19. (anglicky) 

clinicaltrials.gov

  • CHINA NATIONAL BIOTEC GROUP COMPANY LIMITED. Multicenter, Randomized, Double Blind, Parallel Placebo Controlled, Phase III Clinical Trial to Evaluate the Protective Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above. [s.l.]: [s.n.] Dostupné online. Submitted: August 3, 2020. 
  • UNIVERSIDAD PERUANA CAYETANO HEREDIA. Ensayo Clínico de Fase III, Aleatorio, Doble Ciego y Controlado Con Placebo Paralelo, Para Evaluar la Seguridad y la Eficacia Protectora de la Vacuna Inactivada Contra el SARS-CoV-2 en la Población Sana de 18 años o más, en Perú. [s.l.]: [s.n.] Dostupné online. Submitted: August 18, 2020. 

doi.org

dx.doi.org

  • AL KAABI, Nawal; ZHANG, Yuntao; XIA, Shengli. Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. JAMA. 2021-07-06, roč. 326, čís. 1, s. 35–45. Dostupné online [cit. 2021-11-05]. ISSN 0098-7484. DOI 10.1001/jama.2021.8565. 
  • XIA, Shengli; ZHANG, Yuntao; WANG, Yanxia. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. The Lancet. Infectious Diseases. 2021-1, roč. 21, čís. 1, s. 39–51. PMID: 33069281 PMCID: PMC7561304. Dostupné online [cit. 2021-11-05]. ISSN 1473-3099. DOI 10.1016/S1473-3099(20)30831-8. PMID 33069281. 
  • XIA, Shengli; DUAN, Kai; ZHANG, Yuntao. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes. JAMA. 2020-09-08, roč. 324, čís. 10, s. 1–10. PMID: 32789505 PMCID: PMC7426884. Dostupné online [cit. 2021-11-05]. ISSN 0098-7484. DOI 10.1001/jama.2020.15543. PMID 32789505. 

doi.org

  • AL KAABI, Nawal; ZHANG, Yuntao; XIA, Shengli. Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. JAMA. 2021-07-06, roč. 326, čís. 1, s. 35–45. Dostupné online [cit. 2021-11-05]. ISSN 0098-7484. DOI 10.1001/jama.2021.8565. 

mb.com.ph

  • FDA grants EUA to COVID-19 vaccine Sinopharm manufactured by Wuhan affiliate. Manila Bulletin [online]. [cit. 2021-11-05]. Dostupné online. (anglicky) 

nih.gov

ncbi.nlm.nih.gov

  • XIA, Shengli; ZHANG, Yuntao; WANG, Yanxia. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. The Lancet. Infectious Diseases. 2021-1, roč. 21, čís. 1, s. 39–51. PMID: 33069281 PMCID: PMC7561304. Dostupné online [cit. 2021-11-05]. ISSN 1473-3099. DOI 10.1016/S1473-3099(20)30831-8. PMID 33069281. 
  • XIA, Shengli; DUAN, Kai; ZHANG, Yuntao. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes. JAMA. 2020-09-08, roč. 324, čís. 10, s. 1–10. PMID: 32789505 PMCID: PMC7426884. Dostupné online [cit. 2021-11-05]. ISSN 0098-7484. DOI 10.1001/jama.2020.15543. PMID 32789505. 

nmpa.gov.cn

english.nmpa.gov.cn

nytimes.com

  • ZIMMER, Carl; CORUM, Jonathan; WEE, Sui-Lee. Coronavirus Vaccine Tracker. The New York Times. 2020-06-10. Dostupné online [cit. 2021-11-05]. ISSN 0362-4331. (anglicky) 

reuters.com

  • China approves two more domestic COVID-19 vaccines for public use. Reuters. 2021-02-25. Dostupné online [cit. 2021-11-05]. (anglicky) 

web.archive.org

  • Sinopharm's Wuhan affiliate boosts COVID-19 shot annual capacity to 1 billion doses. CNA [online]. [cit. 2021-11-05]. Dostupné v archivu pořízeném z originálu dne 2021-11-19. (anglicky) 

worldcat.org

  • AL KAABI, Nawal; ZHANG, Yuntao; XIA, Shengli. Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. JAMA. 2021-07-06, roč. 326, čís. 1, s. 35–45. Dostupné online [cit. 2021-11-05]. ISSN 0098-7484. DOI 10.1001/jama.2021.8565. 
  • XIA, Shengli; ZHANG, Yuntao; WANG, Yanxia. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. The Lancet. Infectious Diseases. 2021-1, roč. 21, čís. 1, s. 39–51. PMID: 33069281 PMCID: PMC7561304. Dostupné online [cit. 2021-11-05]. ISSN 1473-3099. DOI 10.1016/S1473-3099(20)30831-8. PMID 33069281. 
  • XIA, Shengli; DUAN, Kai; ZHANG, Yuntao. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes. JAMA. 2020-09-08, roč. 324, čís. 10, s. 1–10. PMID: 32789505 PMCID: PMC7426884. Dostupné online [cit. 2021-11-05]. ISSN 0098-7484. DOI 10.1001/jama.2020.15543. PMID 32789505. 
  • ZIMMER, Carl; CORUM, Jonathan; WEE, Sui-Lee. Coronavirus Vaccine Tracker. The New York Times. 2020-06-10. Dostupné online [cit. 2021-11-05]. ISSN 0362-4331. (anglicky)